In the toxicological literature, naturally occurring tetramethylammonium (anion unspecified) is often referred to by the name "tetramine". Unfortunately, this non-systematic or "trivial" name is also used for other chemical entities, including a toxic rodenticide (Tetramethylenedisulfotetramine). Similarly, the acronym "TMA", which is frequently used for tetramethylammonium in the pharmacological literature, may also refer to the investigational drug 3,4,5-trimethoxyamphetamine, which, being a close structural analog of mescaline, has been the subject of numerous publications.
Occurrence
TMA has been detected in or isolated from a number of marine organisms, mostly amongst the Cnidaria and Mollusca, notably in some species of Neptunea (commonly called whelks) that are eaten by humans.[2][3] It has also been found in one plant, the African Courbonia virgata (Cappariaceae).[4] TMA also occurs within the crystal structure Tsaregorodtsevite, a rare Sodalite group mineral with the formula N(CH3)4AlSi5O12 found on Gora Yaruta Mountain, Khanty-Mansi Autonomous Okrug, Russia.[5]
[14C]-labeled TMA has been made by this method.[7]
Although this reaction is suitable for the common halides, tetramethylammonium salts with more complex anions may be prepared by salt metathesis reactions, e.g. tetramethylammonium borohydride has been made from tetramethylammonium hydroxide as shown:[8]
In the TMA cation, the methyl groups are tetrahedrally arranged around the central N atom, as is evident from X-ray crystallographic studies of various of its salts.[11][12] From measurements taken on molecular models, it has been estimated that the diameter of the TMA ion is ~0.6 nm;[13] From more accurate physico-chemical measurements, the ionic radius for TMA is given as 0.322 nm; several thermodynamic parameters for the TMA ion are also recorded.[14][15] The paper by Aue et al. gives a good discussion of the methods by which the ionic radius was determined.[14]
Pharmacology
The pharmacological literature on tetramethylammonium is extensive.[16] In general, TMA is a cholinomimetic whose effects mimic most of those produced by exogenous acetylcholine.[17]
Pharmacological experiments with TMA have been performed using one of its salts, typically the chloride, bromide or iodide, since these anions were not expected to interfere with the actions of the TMA cation. In the early pharmacological literature, however, there are references to the use of "tetramethylammonium hydroxide" or "tetramethylammonium hydrate", which were meant to facilitate comparison between weight-based dosages of different TMA salts,[18] but did not involve the actual use of tetramethylammonium hydroxide, whose strong basicity would have been incompatible with physiological conditions.[2]
A thorough review of the pharmacology of TMA from a toxicological perspective, and current up to 1989, has been given by Anthoni and co-workers.[2] Thus, the effects of TMA on nicotinic and muscarinicACh receptors first stimulate, then block neurotransmission in sympathetic and parasympathetic ganglia, with depolarization. TMA also acts as an agonist at muscarinic receptors in post-ganglionic nerve endings in smooth muscles, cardiac muscle, and exocrine glands. In skeletal muscle, TMA initially causes fasciculations, then paralysis, as a result of the depolarization from stimulation of nicotinic ACh receptors.
Absorption: TMA is readily absorbed from the gastro-intestinal tract.[2] Studies on the rat jejunum indicated that TMA absorption involved a combination of simple diffusion and carrier-mediated transport, with nearly 100% absorption occurring within 60 to 90 minutes. By comparison, tetraethylammonium and tetrapropylammonium ions were only absorbed to the extent of ~30%.[19]
Distribution: Intraperitoneal administration of radio-labeled tetramethylammonium iodide to mice showed that TMA was rapidly distributed to all parts of the body, with the highest concentrations being in the kidney and liver.[7] Similar results were reported by Neef and co-workers using rats.[20]
Metabolism and excretion: Parenteral administration of radio-labeled tetramethylammonium iodide to rats resulted in almost the whole dose being excreted in urine, without any evidence of metabolic transformation.[20]
Toxicology
The human toxicology of TMA (under the name "tetramine") has been studied primarily in the context
of accidental poisoning after ingestion of Neptunea species.[2] Symptoms include the following: nausea, vomiting, headache, vertigo/dizziness, impaired vision/temporary blindness, diplopia, photophobia, lack of balance, feeling of intoxication and urticaria. These symptoms appear within 30 minutes but recovery is usually complete after a few hours. Only one account of human death following ingestion of TMA (from the plant Courbonia virgata) has been recorded.[4]
Although many of these symptoms can be accounted for on the basis of impairment of neurotransmission in the autonomic nervous system, there also seem to be distinct indications of central affects.[2]
In animal studies, parenteral administration of TMA-containing extracts from Neptunea to mice, cats and fish mainly show effects involving skeletal muscles: there are muscular fasciculations, convulsions, loss of balance, motor paralysis and ultimately cessation of respiration.[2]
The lethal oral dose of TMA for humans has been estimated at 3–4 mg/kg.[2][4] The lethal dose for rats was estimated to be ~45–50 mg/kg, p.o., and ~15 mg/kg, i.p.[21]
Acute toxicity
LD50 for TMA chloride: 25 mg/kg (mouse, i.p.); 40 mg/kg (mouse, s.c.).
LC50 for TMA chloride: 462 mg/L for 96 hrs. (Fathead minnow, Pimephales promelas).
[22][23]
^Pautov, L. A.; Karpenko, V. Yu; Sokolova, E. V.; Ignatenko, K. I.; Obshchestva, Zapiski Vserossiiskogo Mineralogicheskogo (1993). "Tsaregorodtsevite, N(CH3)4[Si2(SiO5AlO5)O6]2, a new mineral". Zapiski Vserossiiskogo Mineralogicheskogo Obshchestva. 122 (1): 128–135.
^Banus, M. D.; Bragdon, R. W.; Gibb, T. R. P. (1952). "Preparation of quaternary ammonium borohydrides from sodium and lithium borohydrides". J. Am. Chem. Soc. 74 (9): 2346–2348. doi:10.1021/ja01129a048.
^Fedorynski, M.; Ziolkowska, W.; Jonczyk, A. (1993). "Tetramethylammonium salts: highly selective catalysts for the preparation of gem-dichlorocyclopropanes from electrophilic alkenes and chloroform under phase-transfer catalysis conditions". J. Org. Chem. 58 (22): 6120–6121. doi:10.1021/jo00074a047.
^Koga, Y.; Westh, P.; Nishikawa, K.; Subramanian, S. (2011). "Is a methyl group always hydrophobic? Hydrophilicity of trimethylamine-N-oxide, tetramethyl urea and tetramethylammonium ion". J. Phys. Chem. B. 115 (12): 2995–3002. doi:10.1021/jp108347b. PMID21384939.
^McLean, W. J.; Jeffrey, G. A. (1967). "Crystal structure of tetramethylammonium fluoride tetrahydrate". J. Chem. Phys. 47 (2): 414–417. Bibcode:1967JChPh..47..414M. doi:10.1063/1.1711910.
^ abAue, D. H.; Webb, H. M.; Bowers, M. T. (1976). "A thermodynamic analysis of solvation effects on the basicities of alkylamines. An electrostatic analysis of substituent effects". J. Am. Chem. Soc. 98 (2): 318–329. doi:10.1021/ja00418a002.
^Palomo, J.; Pintauro, P. N. (2003). "Competitive absorption of quaternary ammonium and alkali metal cations into a Nafion cation-exchange membrane". J. Membrane Sci. 215 (1–2): 103–114. doi:10.1016/s0376-7388(02)00606-3.
^Over 1300 citations in PubMed, as of October 2012.
^Drill's Pharmacology in Medicine, 4th Ed. (1971), J. R. DiPalma, Ed., p. McGraw-Hill, NJ.
^Burn, J. H.; Dale, H. H. (1915). "The action of certain quaternary ammonium bases". J. Pharmacol. Exp. Ther. 6: 417–438.